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Glioblastomas (GBMs) are very aggressive tumors that are resistant to conventional chemo- and radiotherapy. 
New molecular therapeutic strategies are required to effectively eliminate the subpopulation of GBM tumor–
initiating cells that are responsible for relapse. Since EGFR is altered in 50% of GBMs, it represents one of the 
most promising targets; however, EGFR kinase inhibitors have produced poor results in clinical assays, with 
no clear explanation for the observed resistance. We uncovered a fundamental role for the dual-specificity 
tyrosine phosphorylation–regulated kinase, DYRK1A, in regulating EGFR in GBMs. We found that DYRK1A 
was highly expressed in these tumors and that its expression was correlated with that of EGFR. Moreover, 
DYRK1A inhibition promoted EGFR degradation in primary GBM cell lines and neural progenitor cells, 
sharply reducing the self-renewal capacity of normal and tumorigenic cells. Most importantly, our data sug-
gest that a subset of GBMs depends on high surface EGFR levels, as DYRK1A inhibition compromised their 
survival and produced a profound decrease in tumor burden. We propose that the recovery of EGFR stability is 
a key oncogenic event in a large proportion of gliomas and that pharmacological inhibition of DYRK1A could 
represent a promising therapeutic intervention for EGFR-dependent GBMs.
Introduction
High-grade gliomas (including glioblastomas – GBMs) are very 
aggressive primary brain tumors that are resistant to chemo- and 
radiotherapy (1). The current standard treatment for GBM includes 
aggressive surgical resection followed by administration of the alkylat-
ing agent, temozolomide, both concurrently and after radiotherapy. 
Bevacizumab, among other agents, is given as a second-line treatment 
after relapse (2, 3). However, this aggressive treatment is only pallia-
tive, as most deaths occur within 2 years of diagnosis, emphasizing 
the need to find new ways of effectively curing this cancer.
One approach is based on the cancer stem cell hypothesis. Sev-
eral groups have demonstrated that there are significant differ-
ences in the differentiation status within a given GBM, with those 
cells resembling normal neural stem cells (NSCs) having a greater 
potential to initiate tumor formation and to maintain its growth 
(4–6). This subpopulation of cells is therefore often referred to 
as tumor-initiating cells (TICs). GBM-TICs share the expression 
of neural markers with NSCs, as well as their capacity for self-re-
newal and multipotent differentiation (7–9), and both of these cell 
types can be enriched in the same culture conditions (10). TICs 
have been associated with tumor relapse after therapy (11, 12) and 
with the invasive and proangiogenic capacity of GBM cells, two 
hallmarks of this type of tumor (13, 14). Therefore, therapeutic 
strategies that target GBM-TICs are of special interest.
The classical GBM view of mutation-driven tumors and the can-
cer stem cell hypothesis are reconcilable. Indeed, the key pathways 
in GBM (p53, PTEN, and pRB-p16) (8, 15) also play important 
roles in the biology of stem cells. A good example is the epidermal 
growth factor receptor (EGFR), one of the most prevalent genes 
altered in GBMs that is mutated and/or amplified in approxi-
mately 50% of primary tumors (16). EGF is one of the main mito-
gens for NSCs and, together with basic fibroblast growth factor 
(bFGF), it maintains the stem-like properties of both NSCs and 
GBM-TICs (10, 17). Indeed, it was recently shown that EGFR 
signaling directly controls the expression of stem cell features in 
GBMs (18) and that the presence of this receptor at the membrane 
could indicate a highly aggressive subpopulation of GBM-TICs 
(19). These findings reinforce the therapeutic potential of target-
ing EGFR in malignant gliomas.
Small-molecule tyrosine kinase (TK) inhibitors are the most 
clinically advanced EGFR-targeted agents to treat GBM. However, 
despite some initial reports on the partial efficacy of these TK 
inhibitors in patients with recurrent tumors (20), later studies have 
not been able to confirm their survival benefits (21, 22). Attempts 
to identify biomarkers that help predict response to EGFR inhibi-
tors have also yielded conflicting results (22–24). It is not even clear 
if the levels of EGFR expression are correlated with GBM respon-
siveness to TK inhibitors (16), suggesting that the receptor may 
contribute to tumor growth independent of its kinase activity.
DYRK1A is a dual-specificity tyrosine phosphorylation–reg-
ulated kinase (DYRK) that plays an important role in the devel-
opment of the central nervous system (CNS), influencing prolif-
eration, neurogenesis, neuronal differentiation, cell death, and 
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synaptic plasticity (25, 26). DYRK1A is also expressed in the adult 
brain and has been linked to cognitive deficits in neurodegenera-
tive disorders and Down syndrome (27). Interestingly, both over-
expression and downregulation of DYRK1A are associated with 
neurological defects, reflecting the extreme gene-dosage sensitivity 
of this protein. Our recent data show that DYRK1A is also impli-
cated in the maintenance and expansion of NSC pools, its haplo-
insufficiency eliciting defects in the self-renewal capacity of NSCs 
from the subventricular zone (SVZ). Dyrk1A heterozygous SVZ 
contained fewer EGFR-positive cells, leading to diminished NSC 
activation in response to EGF. Our data indicate that DYRK1A 
prevents endocytotic degradation of EGFR through the phospho-
rylation of the EGFR-signaling modulator Sprouty2 (SPRY2) (28).
In the present study, we found that interfering DYRK1A com-
promised EGFR stability in established and primary GBM cell 
lines, affecting tumor growth and survival. We also characterize 
the important expression of DYRK1A in astrocytic tumors, espe-
cially in those that contain high levels of EGFR, and we confirm 
that DYRK1A inhibition promotes EGFR degradation. Moreover, 
DYRK1A determined the duration of receptor signaling, its inhibi-
tion strongly and irreversibly inhibiting self-renewal in receptor-de-
pendent GBMs. Finally, we demonstrate that pharmacologically 
blocking DYRK1A kinase activity clearly impairs tumor growth in 
sensitive lines. We believe that our results allow us to propose, for 
the first time, that DYRK1A is a promising therapeutic target in 
GBMs, at least for those depending on EGFR signaling.
Results
DYRK1A modulates EGFR protein levels and the self-renewal of established 
GBM cell lines. To understand the role of DYRK1A in GBMs, we first 
silenced this kinase in established cell lines, grown in the form of neu-
rospheres. The loss of DYRK1A inhibited the self-renewal capacity of 
U87 and U373 cells, although it did not affect LN18 cells (Figure 1A). 
Moreover, DYRK1A inhibition strongly reduced the levels of 
EGFR, evident in Western blots of U87 and U373 cell extracts and 
as assessed by cytometry of puromycin-selected cells (Figure 1B). 
This reduction was produced by posttranslational modifications, 
as lentiviral shDYRK1A did not affect the expression of the EGFR 
gene (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI63623DS1). The absence of 
an effect in LN18 cells could reflect the low levels of EGFR surface 
expression by this cell line (3.4 ± 0.2 % of positive cells) when com-
pared with the sensitive cell lines. Furthermore, reducing DYRK1A 
did not influence BrdU incorporation in U87 cells (Supplemental 
Figure 1B), suggesting that it specifically modulates the self-renewal 
capacity of GBM cells as in normal NSCs (28).
DYRK1A influences U87 tumor growth. We next assessed whether 
the effect of DYRK1A inhibition in vitro was reflected in the 
capacity of GBM neurospheres to form tumors. After checking 
DYRK1A downregulation, we orthotopically transplanted 10,000 
puromycin-selected U87 cells infected with shControl or shDY-
RK1A lentivirus into nude mice. There were phenotypic signs of 
disease 6 weeks after intracranial injection, when the animals were 
sacrificed and the tumor cells detected with a human-specific 
vimentin antibody. The tumors generated by shDYRK1A cells were 
much smaller (80% reduction) than those generated by shControl 
cells (Figure 1C), and immunostaining revealed that shDYRK1A 
neoplastic tissue contained fewer EGFR-positive cells (Figure 1D), 
suggesting that DYRK1A downregulation affected EGFR stabil-
ity in vivo. We performed a competition assay by transplanting a 
small number of GFP-labeled shControl cells (1,000 cells) along 
with shDYRK1A cells (9,000 cells), at a ratio of 1:9, into the brains 
of nude mice. The tumors that arose 1 month later contained 
approximately 60% of GFP-labeled cells (Supplemental Figure 2), 
supporting the notion of a lower tumorigenic capacity of cells with 
reduced levels of DYRK1A.
To further confirm that DYRK1A levels modulate tumor growth, 
3 × 106 U87 cells (shControl or shDYRK1A infected) were implanted 
subcutaneously into the flanks of nude mice. Notably, shDYRK1A 
cells did not form tumors in 2 of 6 animals, whereas shControl cells 
had a 100% penetrance rate in terms of tumor formation. Moreover, 
shDYRK1A tumors grew more slowly than their shControl coun-
terparts, provoking a significant difference at the final endpoint 
(n = 6 [shControl], n = 4 [shDYRK1A]; P = 0.0381) (Figure 1E). Our 
analysis of the tumor tissue revealed that there was less proliferation 
in tissue in which DYRK1A interfered (Figure 1F) and significantly 
higher numbers of apoptotic cells (Figure 1G). Together, these data 
indicate that reducing the amount of DYRK1A affects EGFR levels 
and impairs the self-renewal capacity of GBM cells in vitro. More-
over, the results suggest that high levels of DYRK1A are necessary to 
maintain tumor growth and survival in vivo.
DYRK1A is strongly expressed in a subset of gliomas and its expression is 
correlated with EGFR levels. Although several groups have reported 
that DYRK1A is expressed in the adult mammalian brain in both 
neurons and astrocytes (29, 30), this kinase has not been identified 
in astrocytic tumors. Given the strong effect of DYRK1A down-
regulation on glioma cell lines, we set out to explore the transcript 
levels of DYRK1A in normal tissue (obtained from surgery on 
epileptic patients) and in a panel of gliomas of different grades 
by quantitative RT-PCR (qRT-PCR). The results showed a higher 
expression of DYRK1A in gliomas (especially oligodendrogliomas 
[ODGs] and GBMs), although with a certain degree of variability 
among the tumors tested (Figure 2A).
We investigated the expression of EGFR in the same tissue sam-
ples and, unsurprisingly, EGFR levels were very high in GBMs 
when compared with normal tissue, probably due to the high fre-
quency of genomic amplification in such tumors (16). The EGFR 
gene was also strongly expressed in low-grade astrocytomas and 
even more so in ODGs, suggesting that increased EGFR expres-
sion was common in gliomas of different grades and that it was 
Figure 1
DYRK1A interference affects the levels of EGFR and the tumorigenic 
capacity of established GBM cell lines. (A) GBM cell lines were infected 
with the shControl or shDYRK1A lentivirus, and the capacity to form 
secondary spheres was measured. Bottom Western blot panels illus-
trate the inhibition of kinase expression. (B) Flow cytometric analysis of 
the percentage of EGFR-positive cells after lentiviral infection of 2 GBM 
cell lines. Bottom Western blot panels display the amount of total EGFR 
protein. (C) Images show representative vimentin staining of tumors 
formed after implantation of 10,000 puromycin-selected shControl- or 
shDYRK1A-infected U87 cells. Graphs on the right show the quantifica-
tion of tumor volume. (D) Number of EGFR-positive cells per tumorigenic 
field, with representative images shown on the right. (E) Puromy-
cin-selected shControl- or shDYRK1A-infected U87 cells (3 × 106) 
were implanted into the flanks of nude mice. Tumor size was measured 
once every 4–5 days. Relative tumor volume = tumor volume mea-
sured/tumor volume at day 25. (F) Proportion of BrdU-positive cells in 
shControl and shDYRK1A tumor tissues. (G) Number of activated cas-
pase 3–positive (Act. casp3-positive) cells in the tumor tissues. Scale 
bars: 800 μm (C); 50 μm (D). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Figure 2
DYRK1A is highly expressed in a subset of gliomas and correlates with EGFR expression. (A) DYRK1A transcript levels were determined by 
RT-PCR in glioma samples and normal tissue (obtained during surgery on epileptic patients). HPRT expression was used for normalization. (B) 
Correlation between the levels of EGFR and DYRK1A transcription in the GBM samples. Spearman’s rank correlation parameters are presented 
in the box. (C) Relative DYRK1A expression in EGFR-amplified (amp) and wild-type (WT) GBM samples. (D) IHC images showing an unstained 
control and 5 representative images of DYRK1A staining of 4 different GBMs. Relative DYRK1A RT-PCR values are shown in the brackets. (E) 
Low-magnification images of DYRK1A and EGFR staining of 2 different GBMs. Areas of positive (red box) and negative (blue box) staining of both 
markers are shown at higher magnification. A, astrocytomas. Scale bars: 50 μm. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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not only caused by gene amplification (Supplemental Figure 3), as 
proposed elsewhere (31). Intriguingly, there was a remarkable posi-
tive correlation between DYRK1A and EGFR mRNA levels in GBMs 
(Figure 2B), which was even stronger when gliomas of lower grades 
were also considered (Supplemental Figure 4). Indeed, DYRK1A 
expression was significantly higher in those GBMs that showed 
EGFR amplification (Figure 2C). These analyses suggest that there 
are 2 subgroups of GBMs with regard to DYRK1A presence.
To obtain more evidence of the relationship between 
DYRK1A and EGFR, we analyzed paraffin-embedded tumors by 
immunohistochemistry (IHC). GBM tumor cells exhibited het-
erogeneous labeling of DYRK1A, with positive areas of staining 
detected alongside negative ones. Overall, tumors with very low 
DYRK1A mRNA expression (GBM1) were almost entirely nega-
tive for DYRK1A staining, whereas DYRK1A-expressing tumors 
displayed many areas of positive IHC labeling (Figure 2D). Addi-
tionally, IHC analysis confirmed that most of the samples with 
positive DYRK1A staining also exhibited strong EGFR expression 
and that even within a given tumor, DYRK1A was found mostly 
in areas of strong EGFR staining (Figure 2E). Altogether, these 
data suggest that DYRK1A function is especially relevant for the 
EGFR-dependent subtype of GBMs.
DYRK1A interference suppresses the self-renewal capacity of GBM-TICs. 
Considering the results of DYRK1A interference in GBM cell lines 
and the expression of this kinase in human tissue, we evaluated 
whether DYRK1A levels modulated the behavior of the TICs, 
enriched in neurosphere culture conditions, that are responsible 
for tumor growth and relapse (Figure 3A). All the primary lines 
used in this study could form tumors with high penetrance when 
injected into nude mice. The levels of membrane EGFR were mea-
sured by flow cytometry (Supplemental Figure 5), and 2 distinct 
subgroups of GBM lines were identified, as recently demonstrated, 
based on the different levels of EGFR surface expression (19). One 
of the lines used in this study had very low levels of EGFR (GBM1), 
Figure 3
Characterization of the GBM-TICs used in this study. (A) Representative phase-contrast images of the different GBM-TICs. (B) DYRK1A protein 
expression in some of the GBM-TIC lines and U87 cells. (C) DYRK1A transcriptional levels relative to HPRT. Expression of DYRK1A in normal 
tissue was used for normalization.
Table 1
Genetic background and surface EGFR expression of the different primary GBM-TICs used in this study
Cell line Patient code Origin EGFR amp  % EGFR-positive  PTEN loss  P53 mutation 
   (genomic qPCR) (cytometry) (WB) (WB and IHC)
GBM1 12O-02 12 de Octubre 0 3.8 ± 2.3 1 1
GBM2 12O-15 12 de Octubre 0 14.5 ± 1.9 0 1
GBM3 12O-01 12 de Octubre 1 27.9 ± 4.0 0 0
GBM4 L0627 Mazzoleni et al. 1 41.7 ± 2.2 0 1
GBM5 L0605 Mazzoleni et al. 1 55.2 ± 1.2 1 0
GBM6 L0306 Mazzoleni et al. 1 64.8 ± 2.6 0 0
Primary cultures were obtained by dissociation of human GBM specimens from Hospital 12 de Octubre (12 de Octubre) or were donated by Rosella Galli 
(Mazzoleni et al., ref. 19). 0/1 indicates the absence or presence of the mutation. WB, Western blot.
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Figure 4
Conditional DYRK1A interference affects EGFR levels and the tumorigenic capacity of GBM-TICs. (A) RT-PCR analysis of DYRK1A tran-
scripts 3 days after shDYRK1A induction with doxycycline (Dox). (B) Flow cytometric analysis of the amount of EGFR-positive cells 3 days 
after shDYRK1A induction. (C) RT-PCR analysis of EGFR transcripts 3 days after shDYRK1A induction. (D) Quantification of the capacity to 
form secondary spheres after doxycycline removal. (E) 50,000 GBM5 cells infected with inducible shDYRK1A (GBM5-ishDYRK1A) cells were 
implanted intracranially into nude mice, and 3 weeks later, doxycycline (indicated with an arrow) was added to the drinking water of 1 group of 
mice. Animal survival was evaluated using a Kaplan-Meier survival curve, and the differences in survival times were analyzed with a log-rank 
test (n = 4; P = 0.0316). (F) GBM5-ishDYRK1A cells (3.5 × 106) were injected into the flanks of nude mice. Two weeks later, doxycycline was 
added to the drinking water of 1 group of mice, and tumor size was measured once every 4–5 days. Graph represents the tumor volume after 
doxycycline addition. (G) Western blot analysis of DYRK1A and EGFR protein levels in control and doxycycline-treated tumors. (H) RT-PCR 
analysis of DYRK1A and EGFR transcript levels in control and doxycycline-treated tumors. (I) Number of BrdU-positive cells in the flank tumors. 
(J) Amount of cells with activated caspase 3 in the flank tumors. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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whereas the rest had a higher proportion of EGFR-expressing 
cells, ranging from 15% to 65% (Table 1). DYRK1A expression was 
observed in all but 1 line (GBM1), as measured by Western blot 
analysis (Figure 3B) and RT-PCR (Figure 3C).
To test DYRK1A function in GBM-TIC–enriched cell lines, we 
again used an RNA interference strategy. However, we were not 
able to downregulate DYRK1A in the primary cultures using len-
tiviral constructs and selection of stably-expressing shDYRK1A 
cells, so we decided to use a conditional approach. The expression 
of the red fluorescence protein (RFP) reporter was used to track 
infected cells. Incubation with doxycycline induced a partial reduc-
tion in DYRK1A mRNA levels (Figure 4A), which was correlated 
with a strong reduction in the amount of EGFR-expressing cells 
(Figure 4B) without altering the expression of EGFR transcripts 
(Figure 4C). Three days after shDYRK1A induction, the spheres 
were dissociated and plated again at a clonal dilution in the absence 
of doxycycline. DYRK1A interference clearly inhibited the self-re-
newal capacity of GBM4 and GBM5 cells, but not GBM1 cells, 
which did not express DYRK1A and have the lowest levels of EGFR 
(Figure 4D). These data suggest that DYRK1A levels are essential 
for the expansion of EGFR-expressing GBMs, as downregulation of 
DYRK1A irreversibly affected the clonal growth of TICs.
DYRK1A interference suppresses the tumorigenic capacity of GBM-TICs. 
To address whether the effect of DYRK1A inhibition observed in 
vitro translated into a decreased capacity of primary GBM cells 
to form tumors, 50,000 puromycin-selected shDYRK1A-infected 
GBM5 cells were transplanted into the brains of nude mice. Three 
weeks later, the mice were divided into 2 groups, with doxycycline 
being administered to one of the groups. Kaplan-Meier analysis 
demonstrated that DYRK1A downregulation prolonged the sur-
vival of the GBM-bearing animals. (Figure 4E). To further analyze 
the effect of DYRK1A interference on the growth of GBM-TICs in 
vivo, we injected 3.5 × 106 infected cells into the flanks of nude mice, 
and when tumors reached a minimal volume, the animals were sepa-
rated into 2 groups: control and doxycycline-treated mice, and were 
followed for 3 additional weeks before tumor analysis. Since tumors 
from the doxycycline-treated animals were much smaller at the 
final endpoint, this approach demonstrated that the induction of 
shDYRK1A clearly inhibited tumor progression (Figure 4F and Sup-
plemental Figure 6). Subsequent analysis of the tumor tissue con-
firmed the downregulation of DYRK1A protein after doxycycline 
treatment, which correlated with a significant reduction in EGFR 
protein (Figure 4G) but not of EGFR mRNA transcripts (Figure 4H). 
As in U87 cells, BrdU was incorporated at a much lower level into 
shDYRK1A tumors (Figure 4I), and we observed a clear induction of 
apoptosis (Figure 4J). These results indicate that DYRK1A controls 
GBM-TIC expansion in vivo and that silencing this kinase prevents 
GBM growth and survival, thereby decreasing the tumor burden.
Pharmacological inhibition of DYRK1A kinase activity blocks the self-re-
newal capacity of GBM-TICs and impairs tumor burden. To explore 
the therapeutic potential of DYRK1A, it was important to clar-
ify whether its kinase activity was necessary for the self-renewal 
of normal and tumorigenic stem cells. Therefore, we assessed the 
influence of DYRK1A inhibitor, the β-carboline alkaloid known 
as harmine (32) (shown to work in vivo; ref. 33). We first tested the 
effects of harmine on the growth properties of SVZ-NSCs. Inter-
estingly, harmine (20 μm) had only a small effect on gross viability 
(Figure 5A), but it significantly inhibited the formation of second-
ary spheres (grown in the absence of the drug; Figure 5B) without 
affecting BrdU incorporation (Figure 5C). These results confirm 
our previous findings and further prove that pharmacological 
inhibition of DYRK1A inhibits stem cell behavior (28).
To determine whether DYRK1A inhibition affected the behav-
ior of gliomas, GBM-TIC lines were maintained in the presence of 
harmine for 3 days, before isolating single cells from dissociated 
spheres and replating them at clonal densities in the absence of the 
drug. Harmine significantly inhibited self-renewal in most of the 
primary lines (Figure 6A). As shown in Figure 6B, similar effects 
were obtained with another DYRK1A inhibitor, INDY, a ben-
zothiazole compound (34). Notably, neither harmine nor INDY 
greatly suppressed self-renewal in the DYRK1A-negative GBM1.
To further prove the oncogenic capacity of DYRK1A and deter-
mine the potential therapeutic benefit of targeting its activity in 
GBM-TICs, we injected 50,000 GBM5 cells into the brains of nude 
mice. Two weeks later, the animals were treated systemically with 
harmine (15 mg/kg/day, 5 days per week) or vehicle alone (saline), 
and their survival rates were monitored. A Kaplan-Meier analysis 
suggested that there is a protective effect of harmine, though it did 
not reach significance (Figure 6C). Unfortunately, we could not test 
higher doses of the drug, as they caused tremors in the animals due 
to the drug’s ability to target monoamine oxidase (35). Nevertheless, 
after harmine treatment, brain tumors showed a clear reduction in 
cell proliferation (Figure 6D), as well as the appearance of numer-
ous apoptotic areas (Figure 6E). Interestingly, harmine-treated 
tissue also showed a clear decrease in EGFR staining (Figure 6F). 
Therefore, DYRK1A kinase activity regulated the survival of TICs 
and the oncogenic capacity of EGFR-dependent GBMs.
Figure 5
Harmine impairs the self-renewal capacity of SVZ-NSCs. (A) SVZ neu-
rospheres were treated for 2 days in the presence of different concen-
trations of harmine, and cell viability was measured with a colorimetric 
WST-1 assay. Percentage of inhibition is represented in the graph. (B) 
Formation of secondary spheres after pretreatment with harmine (20 μm 
for 2 days). **P ≤ 0.01. (C) Percentage of BrdU-positive cells in control 
and harmine-treated cells.
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The effect of harmine on GBM-TIC self-renewal depends on EGFR expres-
sion. We investigated the genetic background of our panel of GBM-
TIC lines in an attempt to identify any specific pattern that could 
predict the response to DYRK1A inhibition, other than the pres-
ence of the protein itself in the tumor cells. We found that harmine 
could inhibit secondary clonal formation, regardless of PTEN defi-
ciency or p53 mutations (Table 1), two classic GBM alterations. 
However, there was a very significant positive correlation between 
surface EGFR expression and harmine sensitivity (Figure 6G). This 
strongly reinforces the hypothesis that DYRK1A function modu-
lates self-renewal of EGFR-dependent GBMs, as suggested by our 
earlier studies. To further confirm this proposal, we used one of the 
Figure 6
Pharmacological inhibition of DYRK1A impairs the self-renewal capacity of EGFR-expressing GBM-TICs. GBM primary cells were incubated in 
the presence of (A) harmine or (B) INDY, and 3 days later, the spheres were dissociated and replated in the absence of the drug. A 20-μm con-
centration was chosen based on SVZ-NSC behavior (Figure 5A and Supplemental Figure 7). The number of secondary spheres is represented in 
the graphs. (C) 50,000 GBM5 cells were implanted intracranially into nude mice. Two weeks later, the animals started to receive i.p. injections of 
saline (Control) or harmine (15 mg/kg/day, 5 days per week; indicated by an arrow). Animal survival was evaluated using a Kaplan-Meier survival 
curve, and the differences in survival times were analyzed with a log-rank test (n = 5; P = 0.09). (D) Number of mitotic cells in control or harmine-
treated tumor tissue. (E) Representative images of activated caspase 3 staining in control and harmine-treated tumor tissue. (F) Representative 
images of EGFR staining in control and harmine-treated tumor tissue. (G) Correlation between the amount of membrane EGFR present in the 
different GBM-TIC lines and the percentage of self-renewal inhibition induced by harmine. (H) Percentage of self-renewal inhibition induced by 
harmine in low- or high-passage GBM3 cells. Western blot on the right shows the amount of EGFR and DYRK1A expressed by low- and high-
passage GBM3 cells. Scale bar: 40 μm. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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Figure 7
DYRK1A inhibition stimulates EGFR lysosomal degradation and termination of EGF signaling. Western blot analysis of SVZ-NSCs (A) or U87 
cells (B) that were deprived of growth factors for 12 hours and then exposed to EGF for the indicated durations in the presence or absence of 
harmine. Quantification of EGFR levels relative to β-actin is shown in the bottom graphs. (C) Western blot analysis of the EGFR signaling pathway 
after EGF stimulation of 2 different GBM-TIC lines in the presence or absence of harmine. Quantification of EGFR, p-AKT, and p-ERK1/2 levels 
relative to β-actin is shown on the right. (D) GBM-TICs were preincubated in the presence or absence of harmine. Four hours later, EGF Alexa488 
was added and the cells were fixed at t = 0 or t = 1 hour, 30 minutes. Representative confocal images of EGFR lysosomal targeting in GBM4 cells 
are shown. Quantification of the yellow dots for 2 different GBM-TIC lines is represented by the graph on the right. *P ≤ 0.05. Scale bar: 25 μm.
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ure 7C). These results indicate that 
DYRK1A inhibition alters the dura-
tion of EGFR signaling and suggest 
that the kinetics of EGFR turnover 
determines GBM behavior.
SPRY2 overexpression reverses the effect 
of DYRK1A inhibition on EGFR stability 
and GBM-TIC self-renewal. The mech-
anism of DYRK1A action appears to 
be similar in normal NSCs and GBM-
TICs. We previously demonstrated 
that DYRK1A promoted EGFR sta-
bility in NSCs through the phospho-
rylation of SPRY2 (28), a protein that 
influences receptor turnover through 
the sequestering of the ubiquitin 
ligase C-CBL (38). To assess whether 
similar effects were produced in GBM 
cells, SPRY2 was overexpressed in 
GBM-TICs (Figure 8A), and the effect 
of DYRK1A kinase inhibition was 
analyzed for clonal growth and EGFR 
stability. The influence of harmine 
on EGFR turnover was significantly impaired in the cells overex-
pressing SPRY2 (Figure 8B), suggesting that DYRK1A functions 
upstream of this protein. More importantly, SPRY2 expression 
reversed the suppression of self-renewal induced by harmine (Fig-
ure 8C), demonstrating that DYRK1A controls GBM-TIC self-re-
newal by maintaining higher levels of EGFR at the membrane and 
inhibiting the termination of its downstream signal.
Discussion
Mutations and/or overexpression of EGFR are the most common 
alterations in GBMs, and they have been associated with tumor 
initiation and growth, as well as with resistance to chemo- and 
radiotherapy (39, 40). However, though EGFR kinase inhibitors 
are useful in treating other types of tumors, they offer poor results 
in GBM patients. Moreover, the type of EGFR mutations in GBMs 
often involve deletions in the extracellular domain or cytoplasmic 
tail, whereas mutations in the kinase domain that are commonly 
found in lung cancer, for example, are rare in GBMs (41). These 
results underline the special nature of the EGFR oncogenic net-
work in these neoplasms and suggest that alternative strategies 
must be adopted to effectively target this signaling pathway in 
high-grade gliomas. Our data indicate that DYRK1A is a key ther-
apeutic target for a subset of GBMs (those that are EGFR depen-
dent), and we demonstrate that DYRK1A inhibition increases the 
amount of EGFR targeted for degradation, which causes a large 
percentage of GBM-TICs to lose their self-renewal potential in 
vitro and their tumorigenic capacity in vivo.
Several possibilities have been proposed to explain the resistance 
of GBMs to EGFR inhibitors: coactivation of compensatory path-
ways, upregulation of escape genes, the presence of permanently 
active mutations (like EGFRvIII (16, 42), or the fact that first-gen-
eration TK inhibitors do not bind to the inactive EGFR conforma-
tion that is predominant in GBM cells (43, 44). Additionally, EGFR 
inhibition has been reported to impair GBM cell proliferation more 
than it impairs survival, and this effect on GBM-TICs is reversible 
as tumor cells recover their self-renewal capacity after drug removal 
(45). More recently, it was proposed that reducing EGFR levels (but 
GBM-TIC lines (GBM3) that loses EGFR gene amplification and 
protein expression after long-term culture (without other major 
genomic changes) (Figure 6H and data not shown), a phenomenon 
that has been documented in other primary GBM cultures (36). 
Interestingly, the self-renewal capacity of low-passage GBM3 cells 
was inhibited in the presence of harmine, although no significant 
changes were observed in high-passage EGFR-negative cells (Fig-
ure 6H). These data concur with our previous observation that 
shDYRK1A did not inhibit clonal growth of LN18 cells, which do 
not express EGFR at the membrane (Figure 1A). It also suggests 
that the main effect of DYRK1A inhibition in GBM cells is medi-
ated through EGFR regulation.
DYRK1A controls EGFR turnover in GBM-TICs. DYRK1A interfer-
ence appears to diminish the amount of EGFR protein without 
affecting mRNA levels and, indeed, harmine incubation acceler-
ated receptor degradation in the presence of EGF in SVZ-NSCs 
(Figure 7A), consistent with our earlier observations (28). There-
fore, we checked whether this mechanism was conserved in GBM 
cells. Both DYRK1A interference (Supplemental Figure 8) and 
pharmacological inhibition (Figure 7, B and C) accelerated the 
rate of EGFR degradation following EGF stimulation in the pres-
ence of cycloheximide. In agreement with these results, there was 
a clear increase in the amount of receptors targeted to lysosomes 
after EGF induction in harmine-treated cells as opposed to that 
seen in untreated GBM cells (Figure 7D). Intriguingly, expression 
of the nonlysosomal-targeted EGFRvIII isoform in U87 cells could 
not rescue the inhibition of EGFR signaling (Supplemental Figure 
9A) or the suppression of self-renewal induced by harmine (Sup-
plemental Figure 9B). This suggests that even in the presence of 
the mutation, GBM self-renewal depends on full-length receptor 
signaling, as suggested previously (37). In addition, exposure of 
GBM-TICs to harmine favored the termination of EGFR signaling, 
though with some differences between GBM lines, which appear to 
depend on their genetic background. For instance, harmine mainly 
affected AKT phosphorylation kinetics in the GBM4 line, whereas 
in the PTEN-deficient GBM5 line, the kinetics of phospho-ERK1/
ERK2 was affected, with no clear effect on AKT activation (Fig-
Figure 8
SPRY2 overexpression reverses the effect of harmine on EGFR degradation and GBM-TIC self-re-
newal. (A) GBM5-TICs were infected with control or SPRY2-expressing retrovirus and 48 hours later, 
the cells were analyzed by Western blotting. (B) Control or SPRY2-expressing GBM5-TICs were 
deprived of growth factors for 12 hours and then EGF was added in the presence of harmine for the 
indicated durations. EGFR in the cells was analyzed by Western blotting. (C) Twenty-four hours after 
retroviral infection of GBM5-TICs, the cells were incubated in the presence or absence of harmine 
for 3 days. Dissociated cells were plated in the absence of the drug, and the number of secondary 
spheres formed was counted. ***P ≤ 0.001.
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dampens its inhibitory influence on FGF-induced MAPK activation 
(57). This phosphorylation could potentially regulate SPRY2 bind-
ing to regulatory proteins and help discriminate between the EGF 
and FGF signaling pathways, as described for other residues (58, 59). 
Although SPRY2 is a tumor suppressor in different types of cancer, 
it has a tumor-promoting activity in colon cancer (60). In GBMs, sev-
eral members of the SPRY family are included in a transcriptome 
module that was associated with the EGFR amplification status in 
GBMs (61), suggesting that they could act as oncogenes in at least a 
subset of glial tumors. Further studies are necessary to explore the 
DYRK1A-SPRY2 interaction in GBMs, as well as in other types of 
cancers that might be EGFR dependent.
Our data illustrate that DYRK1A inhibition has a direct effect on 
GBM-TICs, controlling their self-renewal capacity, although there 
were small discrepancies between the effects of DYRK1A inhibi-
tion in vivo and in vitro. There was a clear blocking of proliferation 
and the appearance of apoptotic cells in mouse xenografts after 
DYRK1A suppression, whereas no such effects were detected in 
the GBM-TIC cultures. DYRK1A levels have been shown to mod-
ulate the apoptosis of retinal ganglion cells during development 
through a regulatory phosphorylation of caspase 9 (33), and it is 
therefore possible that it also has a protective role in the tumor 
environment. Moreover, we cannot rule out the possibility that 
DYRK1A has a paracrine effect in tumors and that it could par-
ticipate in other aspects of GBM biology, like angiogenesis. It is 
worth noting that harmine-containing plants have been used as 
traditional medicine in anticancer therapy. Furthermore, harmine 
has been shown to inhibit neovessel formation in vitro and in vivo 
through the regulation of several angiogenic factors and inflam-
matory cytokines (62). Although it is not known if DYRK1A is the 
direct mediator of such effects, future studies are needed  to ascer-
tain the role of DYRK1A in apoptosis or tumor vessel formation 
in glial tumors and whether its activity involves EGFR stability.
In recent years, much effort has been made to elucidate the 
molecular alterations in GBMs and has resulted in a large number 
of novel, targeted molecular therapies. However, none of these has 
translated into clinical benefits. The case of EGFR is an exemplary 
one, in that the therapeutic response was minimal despite the high 
expectations that EGFR kinase inhibitors would provide impor-
tant clinical benefits. Here, we propose that recovery of EGFR sta-
bility (more than kinase activity per se) is an essential oncogenic 
event in a large percentage of GBMs. Several molecules can modu-
late the cell surface expression of EGFR, but none of them can be 
as easily targeted as DYRK1A. Therefore, targeting this kinase with 
small molecules, alone or in combination with EGFR inhibitors or 
DNA-damaging agents, could be extremely beneficial in treating 
EGFR-dependent GBMs.
Methods
Patients and tumor samples
Samples from patients diagnosed with brain tumors were provided by the 
Hospital de Madrid Tumor Bank Network, Hospital Universitario 12 de 
Octubre (Madrid, Spain) and Hospital Universitario La Fe (Valencia, Spain).
Primary lines and culture conditions
GBM1, GBM2, and GBM3 were obtained by cell dissociation of human 
GBM surgical specimens from patients treated at the “Hospital 12 de 
Octubre” (Madrid, Spain). Fresh tissue samples were digested enzymati-
cally using Accumax (Millipore), and the isolated cells were purified by a 
not TK inhibition) induces autophagic cancer cell death through 
modulation of glucose transport (46). The data presented here sug-
gest that DYRK1A blockade exerts an irreversible effect on GBM 
cells, since they lose their clonogenic capacity even after removing 
the pharmacological inhibitors or the shRNA inducer. Without rul-
ing out the possibility that DYRK1A affects other signaling path-
ways in the GBM-TICs, our data show that the blockade inhibits 
EGFR stability, and therefore targeting EGFR for degradation 
could be more effective than inhibiting its kinase activity. In fact, 
a kinase-defective EGFR can stimulate DNA synthesis (47) and 
enhance cell survival (48). In this regard, it was proposed that one 
potential mode of action of the monoclonal antibodies directed 
against EGFR, which are currently undergoing phase III trials for 
glioma treatment, may involve their ability to target EGFR for lys-
osomal degradation (49). We propose that small molecules target-
ing DYRK1A kinase activity could be a good strategy for inhibiting 
EGFR stability. We used the β-carboline alkaloid harmine (32) and 
INDY, a benzothiazole compound (34), with harmine being able to 
inhibit GBM tumor growth and survival. Harmine and INDY have 
been shown to bind to the ATP pocket of DYRK1A and inhibit its 
kinase activity (50). They have limited use in vivo, however, as sys-
temic INDY treatment does not reach the brain and harmine is a 
potent inhibitor of monoamine oxidase (35). However, molecular 
docking analysis showed that harmine has many degrees of free-
dom in the ATP-binding pocket of DYRK1A and that this could be 
exploited to more selectively inhibit the kinase (50).
Our data support the notion that maintaining high levels of 
EGFR at the membrane is a key oncogenic event, at least in a sub-
set of GBMs. EGFR (also called ErbB1) belongs to the family of 
ErbB proteins, whose members differ in their signaling potency 
depending on distinct mechanisms that negatively regulate the 
receptor’s fate. For example, only EGFR is strongly coupled to the 
C-CBL adaptor protein, and unlike other ErbB members, it is effec-
tively targeted for lysosomal degradation (51). Impaired endocytic 
downregulation of receptors is frequently associated with cancer. 
Indeed, dominant-negative forms of CBL are found as oncogenes in 
human myeloid neoplasms (52). However, no such mutations have 
been found in GBMs, although the 19q13 allele containing C-CBL is 
frequently lost in these tumors (53). More recently, the transmem-
brane glycoprotein LRIG1 has been found to be attenuated in many 
astrocytomas and to control CBL recruitment and EGFR downregu-
lation (54); also, LRIG1, which controls CBL recruitment and EGFR 
downregulation, has been found to be attenuated in many astro-
cytomas (54). Likewise, a molecule that targets EGFR to lysosomal 
degradation, MIG6, inhibits anchorage-independent GBM growth 
and is frequently deleted in these tumors (56). Thus, like DYRK1A 
inhibition, upregulation of LRIG1 or MIG6 limits the activation of 
EGFR and causes a strong inhibition of GBM-TIC self-renewal in 
vitro and impairs tumor survival in vivo, which reinforces the ther-
apeutic potential of targeting EGFR stability in a subset of GBMs.
Our biochemical results suggest that DYRK1A functions upstream 
of SPRY2 to modulate EGFR lysosomal targeting and GBM-TIC 
self-renewal. These results are consistent with our previous findings 
in normal neural progenitors (28). SPRY2 belongs to a family of 
growth factor–mediated mitogen-activated protein kinase (MAPK) 
modulators. Paradoxically, SPRY2 also exerts a positive effect on 
EGFR signaling through its interaction with proteins like C-CBL 
and the hepatocyte growth factor–regulated tyrosine kinase sub-
strate (HRS), which are involved in the endocytosis and degradation 
of EGFR (38). Phosphorylation of SPRY2 on THR75 by DYRK1A 
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Heterotopic xenografts. Cells (3 × 106) were resuspended 1:1 in culture 
media and Matrigel (BD) and then subcutaneously injected into athymic 
nude Foxn1nu mice. The tumor volume was measured with a caliper when 
it reached a visible size.
Mouse drug treatments
Harmine treatment. Two weeks after intracranial injection, mice were 
treated with harmine (15 mg/kg/day) or vehicle (saline) i.p. until they 
were sacrificed.
Doxycycline treatment. Mice were given 2 mg/ml doxycycline in their 
drinking water at the indicated times.
Statistics
A Kruskal-Wallis test was used to analyze the expression of DYRK1A and 
EGFR in the human samples. A Spearman’s correlation test was used to 
assess the relationship between the expression of DYRK1A and EGFR. The 
survival of nude mice was analyzed by the Kaplan-Meier method and eval-
uated with a 2-sided log-rank test. A 2-tailed Student’s t test was performed 
for statistical analysis of the in vitro studies. The data in the graphs are pre-
sented as the means ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. Statistical 
values of P > 0.05 were not considered significant.
Study approval
The present studies with animals and human samples were reviewed and 
approved by the Research Ethics and Animal Welfare Committee at the 
Instituto de Salud Carlos III, Madrid, in agreement with the European 
Union and national directives. The human tissues were procured after 
obtaining the patients’ written consent and with the approval of the ethics 
committees of each participating hospital (Clinical Research Ethics Com-
mittee from Hospital Universitario 12 de Octubre, Madrid; Hospital Uni-
versitario La Fe, Valencia; and Hospital de Madrid, Madrid).
Further information can be found in the Supplemental Methods.
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Ficoll gradient (GE Healthcare) and plated at a density of 50,000 cells per 
milliliter in culture medium consisting of Neurobasal (Invitrogen) sup-
plemented with B27 (1:50) (Invitrogen); GlutaMAX (1:100) (Invitrogen); 
penicillin-streptomycin (1:100:Lonza); 0.4% heparin (Sigma-Aldrich); and 
40 ng/ml EGF and 20 ng/ml bFGF2 (complete medium; Peprotech). The 
GBM4, GBM5, and GBM6 primary lines were provided by Rosella Galli 
(San Raffaele Scientific Institute, Milan, Italy) (19), while the U87, U373, 
and LN18 cell lines were obtained from the ATCC. All human cell lines 
were grown in complete medium and were passaged after enzymatic dis-
aggregation using Accumax (Millipore). Mouse SVZ primary neural stem 
cell cultures were obtained as described previously (63) and cultured in 
complete medium supplemented with 20 ng/ml EGF and 10 ng/ml bFGF2.
Reagents
Harmine hydrochloride (TCI Europe) and INDY (34) were resuspended in 
water and DMSO, respectively. They were used at a final concentration of 
20 μM unless otherwise noted. PCR primers and antibodies used through-
out the study are listed in Supplemental Tables 1 and 2.
Retroviral and lentiviral vectors
The lentiviral vectors pLKO.1-shRNASCRAMBLE and pLKOshDYRK1A 
(Sigma-Aldrich) were used for the stable DYRK1A interference. For 
DYRK1A–inducible interference, the pTRIPZ lentiviral shRNAmir (V3THS-
376671 clone) was used (Open Biosystems). Infected cells were selected 
with 1 μg/ml of puromycin, and shRNAmir expression was induced by 
1 μg/ml of doxycycline (Sigma-Aldrich). Retroviral vectors used were: 
pLPCX (Clontech), pLPCX-SPRY2 (a gift from J.M. Rojas, ISCIII, Madrid, 
Spain), MSCV-PIG, and MSCV-EGFRvIII (Addgene).
EGFR degradation assays
Growth factor–starved NSC and GBM cells were incubated in the presence 
or absence of doxycycline (12 hours) or harmine (4 hours). Cycloheximide 
(30 μg/ml; Sigma-Aldrich) was added to the cells and 1 hour later, EGF 
(100 ng/ml) was added for the indicated durations. The cells were chilled 
on ice and cell pellets were processed for Western blot analysis.
EGFR lysosomal targeting
Growth factor–starved primary cultures were incubated in the presence or 
absence of harmine (20 μM) for 3 hours. Afterwards, 100 ng/ml of Alexa 
Fluor 488–conjugated EGF (Invitrogen) and 50 nM of LysoTracker Red 
(Invitrogen) were added, and cells were incubated at 4°C for 30 minutes. The 
cultures were then washed twice with cold PBS and either fixed immediately 
(t = 0) or incubated at 37°C in 5% CO2 for an additional 90 minutes to allow 
EGFR internalization before fixing. DAPI (0.1 μg/ml) was used to stain the 
nuclei. Fluorescence images were obtained on a confocal microscopy (Leica 
TCS SP5 AOBS) and yellow colocalization spots were quantified.
Mouse xenograft assays
Orthotopic xenografts. Stereotactically guided intracranial injections in athy-
mic nude Foxn1nu mice (Harlan Iberica) were performed by administering 
10,000 (U87) to 50,000 (primary lines) cells resuspended in 2 μl of culture 
medium. The injections were made into the striatum (coordinates: A-P, 
–0.5 mm; M-L, +2 mm; D-V, –3 mm; related to Bregma) using a Hamilton 
syringe, and the animals were sacrificed at the onset of symptoms.
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